Moran, Diarmuid M.

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

Shah, M. A., Shitara, K., Ajani, J. A., Bang, Y.-J., Enzinger, P., Ilson, D., Lordick, F., Van Cutsem, E., Gallego Plazas, J., Huang, J., et al. (2023) · Nature Medicine

Gastric Cancer Management and OutcomesEsophageal Cancer Research and Treatment

Cited by 681

KRAS Mutation Status Is Associated with Enhanced Dependency on Folate Metabolism Pathways in Non–Small Cell Lung Cancer Cells

Moran, D. M., Trusk, P. B., Pry, K., Paz, K., Sidransky, D., & Bacus, S. S. (2014) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsCancer, Hypoxia, and Metabolism

Cited by 64

Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells

Moran, D. M., & Maki, C. G. (2010) · Molecular Cancer Therapeutics

Cancer-related Molecular PathwaysUbiquitin and proteasome pathways

Cited by 35